MTF NEUROsis

NASDAQ OMX confirmed this week that it will close NEURO, its London based MTF, at the end of next month. Given that it was backed by the mighty NASDAQ OMX why did it fail and is this the end of the MTF model as we know it? It didn’t help that NEURO launched at the height (depth) of the credit crisis, but it always seemed to struggle to develop a real identity of its own. Chi-X was first and Turquoise had a bunch of investment banks priming it with liquidity whilst BATS has... Read More

Battle Stations

Had a couple of productive (and fun) days at TradeTech Europe last week. The Fidessa airship flying round the exhibition hall served as a good reminder to everyone that the switch by the LSE Group onto its spangly new Millennium Exchange platform is fast approaching. This new matching engine will also be powering the LSE’s own MTF, Turquoise, which will be going live ahead of the LSE main market in September. Last week also saw the LSE Group introduce a revised pricing scheme... Read More

Trading US Stocks European Style

Few can have missed the announcements from the LSE’s Turquoise and NYSE Arca Europe that they will each soon begin trading US stocks. Both venues will aim to attract the HFT/algo community which will be able to exploit differences in prices between these platforms and their US counterparts. On this point, the Turquoise plan is particularly aggressive as it will allow users to trade for free initially. This shows just how determined senior management at the LSE Group really are,... Read More

Less haste more speed

Quite a lot has been written over recent weeks about the London Stock Exchange’s market share and last week helped to clarify some of the issues. Prior to this period the LSE had enjoyed a temporary boost in volumes driven by the triple witching hour on March 19th when many traders go to the LSE in order to cover their equity options positions. But this was just a small kink in the underlying trend which shows the fragmentation of FTSE 100 stocks seemingly on a never ending... Read More

Copyright © 2011 Fidessa group plc. All rights reserved.

The information contained within this website is provided for informational purposes only. Fidessa will use reasonable care to ensure that information is accurate at the time it is made available, and for the duration that it remains on the site. The information may be changed by Fidessa at any time without notice. We also reserve the right to close the website at any time. No representation or warranty, expressed or implied, is given on behalf of Fidessa or any of its respective directors, employees, agents, or advisers as to the accuracy or completeness of the information or opinions contained herein or its suitability for any purpose and, save in the case of fraud, all liability for direct, indirect, special, consequential or other loss or damages of whatever kind that may arise from use of the website is hereby excluded to the fullest extent permitted by law. Any decisions you make based on the information in this website are your sole responsibility and information on the website should not be relied upon in connection with any investment decision.

The copyright of this website belongs to Fidessa. All other intellectual property rights are reserved.

Fragulator® is a registered trademark of Fidessa group plc.

Reproduction or redistribution of this information is prohibited except with written permission from Fidessa.